Kronos Bio (NASDAQ:KRON - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.13), Zacks reports. Kronos Bio had a negative net margin of 867.66% and a negative return on equity of 64.55%. The company had revenue of $2.27 million during the quarter, compared to analyst estimates of $1.00 million.
Kronos Bio Price Performance
KRON traded down $0.01 on Friday, hitting $0.87. 388,368 shares of the stock were exchanged, compared to its average volume of 271,865. Kronos Bio has a 12 month low of $0.69 and a 12 month high of $1.60. The business has a 50-day moving average of $0.98 and a two-hundred day moving average of $0.96. The firm has a market capitalization of $52.53 million, a price-to-earnings ratio of -0.61 and a beta of 1.79.
About Kronos Bio
(
Get Free Report)
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
Read More
Before you consider Kronos Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kronos Bio wasn't on the list.
While Kronos Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
